Tender Details

Country: USA
Summary: Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines THRIVE
UST Ref No: 130211713
Deadline: 22 Dec 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: ARPA-H-SOL-25-122
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Amendment 4: PowerPoint presentation
The purpose of this amendment is to add a virtual PowerPoint presentation to the evaluation process. This additional step requires submission of PowerPoint presentation slides, a Gantt chart, and an optional appendix in PDF format. For full details, please see the revised ISO, with changes identified in red font, attached to this amendment.
Please note, the deadline for the PowerPoint presentation submission is December 22, 2025 at 3:00PM E.T. The virtual PowerPoint presentations are expected to be held from January 5th to January 16th, 2026.
----------------------------------------------------------------------------------------------------------------
Amendment 3: Team Organization and Capabilities Section
The purpose of this amendment is to clarify that the following information, requested in the Teaming Organization and Capabilities section of the Solution Summary, may be included in the Table for Key Personnel:
Provide the name, position, and institution of each key team member and describe in 1-2 sentences the skills and experience they bring to the team.
If included in the Table for Key Personnel, this information will not count towards the (3) page Solution Summary page limit, however, the Table for Key Personnel must still not exceed (1) page in length.
In addition, the Q&A deadline is extended to October 30, 2025 at 11:59PM ET.
-----------------------------------------------------------------...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines THRIVE - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines THRIVE. This tender is published on USARFP under UST Ref No: 130211713 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-12-22.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.